Enoxaparin Sodium Injection
Product Images NDC 71288-433

Product Visual Gallery

This gallery contains 38 technical images submitted to the FDA as part of the official labeling for Enoxaparin Sodium (NDC 71288-433). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Meitheal Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel – Enoxaparin Sodium Injection, Usp 100 mg Blister Pack Label (Enox 100mg Ht Blister V2)

This is a product with the NDC code 71288-436-91 for Enoxaparin Sodium Injection, USP. It has a concentration of 100 mg per mL and is indicated for prescription use only.*

FDA Label Image

Principal Display Panel – Enoxaparin Sodium Injection, Usp 100 mg Carton (Enox 100mg Ht Carton V2)

This text seems to be a description of a medication product labeled as Enoxaparin Sodium Injection, USP containing 100 mg per mL for subcutaneous use. The product is prefilled in syringes with an automatic safety device. It provides dosage and administration instructions, storage requirements, and warning information. The content of the syringes does not contain natural rubber latex. Additional details such as lot number and other technical specifications are also mentioned.*

FDA Label Image

Principal Display Panel – Enoxaparin Sodium Injection, Usp 120 mg Blister Pack Label (Enox 120mg Ht Blister V2)

FDA Label Image

Principal Display Panel – Enoxaparin Sodium Injection, Usp 120 mg Carton (Enox 120mg Ht Carton V2)

FDA Label Image

Principal Display Panel – Enoxaparin Sodium Injection, Usp 150 mg Blister Pack Label (Enox 150mg Ht Blister V2)

FDA Label Image

Principal Display Panel – Enoxaparin Sodium Injection, Usp 150 mg Carton (Enox 150mg Ht Carton V2)

This text appears to be a pharmaceutical product description for Enoxaparin Sodium Injection in pre-filled syringes. The text includes details about dosage and administration instructions, storage conditions, and product specifications. The product is indicated for subcutaneous use and contains 50mg per mL of Enoxaparin Sodium. It also mentions a warning to keep the product at specific temperatures and details about the container features. The product is sterile, non-pyrogenic, and includes an automatic safety device. The text provides information on the NDC number, product presentation, and lot details for identification purposes.*

FDA Label Image

Principal Display Panel – Enoxaparin Sodium Injection, Usp 30 mg Blister Pack Label (Enox 30mg Ht Blister V2)

FDA Label Image

Principal Display Panel – Enoxaparin Sodium Injection, Usp 30 mg Carton (Enox 30mg Ht Carton V2)

FDA Label Image

Principal Display Panel – Enoxaparin Sodium Injection, Usp 40 mg Blister Pack Label (Enox 40mg Ht Blister V2)

This text provides information about a prescription drug called Enoxaparin Sodium Injection, USP. It contains 40 mg per 0.4 mL. This medication is for prescription use only.*

FDA Label Image

Principal Display Panel – Enoxaparin Sodium Injection, Usp 40 mg Carton (Enox 40mg Ht Carton V2)

This text appears to describe a medication in the form of prefilled syringes containing Enoxaparin Sodium Injection, USP, with a concentration of 40mg per 0.4 mL. The syringes come with an automatic safety device for subcutaneous use. The text includes information about dosage and administration, storage conditions, container materials, and warnings. The product is sterile, non-pyrogenic, preservative-free, and DEHP-free. It is advised to store the syringes in the original packaging until ready for use. The text also provides product codes, lot numbers, and expiration dates. Please consult healthcare professionals for accurate medical advice and usage information.*

FDA Label Image

Principal Display Panel – Enoxaparin Sodium Injection, Usp 60 mg Blister Pack Label (Enox 60mg Ht Blister V2)

This text is a drug label for Enoxaparin Sodium Injection, USP. It is intended for subcutaneous use.*

FDA Label Image

Principal Display Panel – Enoxaparin Sodium Injection, Usp 60 mg Carton (Enox 60mg Ht Carton V2)

FDA Label Image

Principal Display Panel – Enoxaparin Sodium Injection, Usp 80 mg Blister Pack Label (Enox 80mg Ht Blister V2)

This is a description of Enoxapar Sodium Injection, USP with the National Drug Code (NDC) 71288-435-91.*

FDA Label Image

Principal Display Panel – Enoxaparin Sodium Injection, Usp 80 mg Carton (Enox 80mg Ht Carton V2)

FDA Label Image

Figure A (Enox Ifu A)

FDA Label Image

Figure B (Enox Ifu B)

FDA Label Image

Figure C (Enox Ifu C)

FDA Label Image

Figure D (Enox Ifu D)

FDA Label Image

Figure E (Enox Ifu E)

FDA Label Image

Figure F (Enox Ifu F)

FDA Label Image

Figure G (Enox Ifu G)

FDA Label Image

Figure H (Enox Ifu H)

FDA Label Image

Figure I (Enox Ifu I)

FDA Label Image

Figure J (Enox Ifu J)

FDA Label Image

Figure K (Enox Ifu K)

FDA Label Image

Figure L (Enox Ifu L)

FDA Label Image

Figure M (Enox Ifu M)

FDA Label Image

Figure N (Enox Ifu N)

FDA Label Image

Syringe Parts (Enox Ifu Parts)

FDA Label Image

Figure 1 (Enox Pi Fig 1)

This is a structured data table showing different subgroups based on factors such as sex, age, infarct location, diabetes status, prior myocardial infarction, fibrinolytic agent used, time to treatment, percutaneous coronary intervention (PCI) within 30 days, and overall outcomes. The table also includes relative risk values and the number of patients in each subgroup. The data suggests a comparison between different treatment groups (i.e., UFH and Enoxaparin) in terms of risk reduction. The findings indicate variations in outcomes based on different factors within the subgroups.*

FDA Label Image

Figure 2 (Enox Pi Fig 2)

This is data showing hazard distribution function, including the results of a log-rank test comparing Enoxaparin and UFH treatments. The chart displays the time to Death or Myocardial Re-infarction over a period of 360 days with the number at risk for each treatment group at different time points.*

FDA Label Image

Figure A (Enox Pi Fig A)

FDA Label Image

Figure B (Enox Pi Fig B)

FDA Label Image

Figure C (Enox Pi Fig C)

FDA Label Image

Figure D (Enox Pi Fig D)

FDA Label Image

Figure E (Enox Pi Fig E)

FDA Label Image

Structural Formula 1 (Enox Structure 1)

FDA Label Image

Structural Formula 2 (Enox Structure 2)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.